Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic’s many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicYou are an essential partner in our work to find answers for our patients. Donate now.
Mayo Clinic's MS group is recognized as one of the strongest centers of demyelinating disease in the world. Four major goals of our center include:
Promoting remylination in MS patients
Natural Human Monoclonal Antibody (HIgM22)l Human Monoclonal Antibody (HIgM22) Development of recombinant protein (Pease and Rodriguez) Manufacture in GMP facility at the University of Minnesota Toxicology underway all negative to date
Planned Phase I clinical trial in early 2009
Understanding the immune-pathogenesis of MS and related CNS demyelinating disorders by detailed analysis of pathological specimens from patients and the most pertinent of animal models
Four distinct pathologic patterns identified (Lucchinetti)
Pattern II associated with immunoglobulin deposition and complement responds to plasma exchange (Rodriguez)
Apoptosis important in other patterns thus anti-apoptotic drugs (Ritonovir) being investigated (Howe)
Kallidreins involved in damage (Scarisbrick)
Understanding the genetic factors that determine whether the disease has a benign or severe course
Epidemiology of MS in Olmsted County (1995 to present) – Rodriquez and Pittock
Genetic variations of interferon gamma associated with prognosis (Kantarci and Weinshenker)
Two genes indentified with LOD scores of >13 associated with remyelination in mice (Bieber)
Developing new symptomatic and curative therapies for MS and related disorders
Aspirin trial for MS-related fatigue funded by the National MS Society (200 patients, placebo controlled, examining cytokines (Wingerchuck and Rodriguez)
Calcium and Vitamin D – shown to reduce the risk of MS and prevents the frequent complication of osteoporosis
Neuromyelitis Optica (Devic's Disease)
New antibody diagnostic marker – NMO-IgG (Lennon)
Aquaporin 4 is the antigen target
First demyelinating disease with a serum diagnostic marker
Treatment very different from MS, therefore, important to identify
Genetic variants of aquaporin 4 may identify patients at risk
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.